BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People’s Republic of China, the United States, and internationally.
Excellent balance sheet with limited growth.
Share Price & News
How has BeiGene's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 6160's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 6160 exceeded the Hong Kong Biotechs industry which returned 25% over the past year.
Return vs Market: 6160 exceeded the Hong Kong Market which returned -4% over the past year.
Price Volatility Vs. Market
How volatile is BeiGene's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is BeiGene undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: 6160 (HK$104.3) is trading above our estimate of fair value (HK$74.95)
Significantly Below Fair Value: 6160 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: 6160 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 6160 is unprofitable, so we can't compare its PE Ratio to the Hong Kong market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 6160's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 6160 is overvalued based on its PB Ratio (4.7x) compared to the HK Biotechs industry average (2.9x).
How is BeiGene forecast to perform in the next 1 to 3 years based on estimates from 20 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 6160 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 6160 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 6160 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 6160's revenue (44.5% per year) is forecast to grow faster than the Hong Kong market (10.6% per year).
High Growth Revenue: 6160's revenue (44.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 6160 is forecast to be unprofitable in 3 years.
How has BeiGene performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 6160 is currently unprofitable.
Growing Profit Margin: 6160 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 6160 is unprofitable, and losses have increased over the past 5 years at a rate of -61.6% per year.
Accelerating Growth: Unable to compare 6160's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6160 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-30.2%).
Return on Equity
High ROE: 6160 has a negative Return on Equity (-40.59%), as it is currently unprofitable.
How is BeiGene's financial position?
Financial Position Analysis
Short Term Liabilities: 6160's short term assets ($3.6B) exceed its short term liabilities ($451.8M).
Long Term Liabilities: 6160's short term assets ($3.6B) exceed its long term liabilities ($788.4M).
Debt to Equity History and Analysis
Debt Level: 6160's debt to equity ratio (8.9%) is considered satisfactory.
Reducing Debt: 6160's debt to equity ratio has reduced from 50.1% to 8.9% over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6160 has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if 6160 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is BeiGene's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 6160's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate 6160's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 6160's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 6160's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 6160's dividend in 3 years as they are not forecast to pay a notable one for the Hong Kong market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
John Oyler (51yo)
Mr. John V. Oyler Co-Founded BeiGene, Ltd. and has been its Chief Executive Officer since 2010. Mr. Oyler Co-founded BioDuro, LLC and served as its Chief Executive Officer and President from 2005 to 2009. ...
CEO Compensation Analysis
Compensation vs Market: John's total compensation ($USD12.58M) is above average for companies of similar size in the Hong Kong market ($USD767.04K).
Compensation vs Earnings: John's compensation has been consistent with company performance over the past year.
|GM of China & President||2.08yrs||US$9.13m||0.054% $55.9m|
|CFO & Chief Strategy Officer||4.92yrs||US$4.19m||0.00071% $734.5k|
|Chief Medical Officer of Hematology||3.75yrs||US$3.61m||0.019% $20.0m|
|Vice President of Finance & Accounting||no data||no data||no data|
|Investor Contact||no data||no data||no data|
|Senior VP & General Counsel||no data||no data||no data|
|VP and Global Head of Quality & Regulatory Compliance||3yrs||no data||no data|
|Head of Discovery Biology & Senior VP||9.67yrs||no data||no data|
Experienced Management: 6160's management team is considered experienced (4.9 years average tenure).
|Independent Non-Executive Director & Member of the Scientific Advisory Committee||0.33yr||US$372.47k||0.040% $40.9m|
|Independent Non-Executive Director & Member of the Scientific Advisory Committee||0.33yr||US$354.97k||0.00092% $951.7k|
|Independent Non-Executive Director||7.33yrs||US$362.47k||0.35% $358.6m|
|Non Executive Director & Chairman of the Commercial Advisory Committee||0.33yr||no data||no data|
|Independent Non-Executive Director & Member of the Commercial Advisory Committee||2.17yrs||US$356.64k||no data|
|Independent Non-Executive Director & Member of the Commercial Advisory Committee||0.33yr||US$367.47k||no data|
|Independent Lead Director & Member of the Commercial Advisory Committee||0.33yr||US$357.47k||0.00092% $951.7k|
|Independent Non-Executive Director & Member of the Scientific Advisory Committee||5.67yrs||US$370.80k||no data|
Experienced Board: 6160's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 29.8%.
BeiGene, Ltd.'s company bio, employee growth, exchange listings and data sources
- Name: BeiGene, Ltd.
- Ticker: 6160
- Exchange: SEHK
- Founded: 2010
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$13.348b
- Listing Market Cap: US$103.446b
- Shares outstanding: 77.59m
- Website: https://www.beigene.com
Number of Employees
- BeiGene, Ltd.
- No.30 Science Park Road
- Zhong-Guan-Cun Life Science Park
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BGNE||NasdaqGS (Nasdaq Global Select)||Yes||SPONSORED ADR||US||USD||Feb 2016|
|49BA||DB (Deutsche Boerse AG)||Yes||SPONSORED ADR||DE||EUR||Feb 2016|
|BGNE N||BMV (Bolsa Mexicana de Valores)||Yes||SPONSORED ADR||MX||MXN||Feb 2016|
|49B||DB (Deutsche Boerse AG)||Ordinary Shares||DE||EUR||Aug 2018|
|6160||SEHK (The Stock Exchange of Hong Kong Ltd.)||Ordinary Shares||HK||HKD||Aug 2018|
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology cancer therapeutics in the People’s Republic of China, the United States, and internationally. Its commercial products include BRUKINSA to treat R/R mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; ABRAXANE to treat breast cancer; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; KYPROLIS to treat multiple myeloma; BLINCYTO to treat acute lymphocytic leukemia; SYLVANT to treat idiopathic multicentric castleman disease; and QARZIBA to treat neuroblastoma. The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat various lymphomas; Tislelizumab, an anti-PD-1 antibody to treat various solid and hematological cancers; Pamiparib, an inhibitor of PARP1 and PARP2 to treat various solid tumors; Lifirafenib and BGB-3245 to treat various malignancies, such as melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumor. In addition, its clinical stage drug candidates include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; BGB-A1217, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; and BGB-A445, an OX40 agonist antibody to treat solid tumors. The company has collaborations with Celgene Corporation; Merck KGaA; Mirati Therapeutics, Inc.; BioAtla, LLC; Zymeworks, Inc.; Ambrx, Inc.; Atreca Inc.; IGM Biosciences, Inc.; and Hutchison China MediTech Limited. BeiGene, Ltd. was founded in 2010 and is based in Beijing, the People’s Republic of China.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/06 14:09|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.